HUMALOG LISPRO, NPL: 109 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
109
Total FAERS Reports
6 (5.5%)
Deaths Reported
47
Hospitalizations
109
As Primary/Secondary Suspect
3
Life-Threatening
6
Disabilities
First Report: 1998 · Latest Report: 20140605
What Are the Most Common HUMALOG LISPRO, NPL Side Effects?
#1 Most Reported
Blood glucose increased
26 reports (23.9%)
#2 Most Reported
Hypoglycaemia
9 reports (8.3%)
#3 Most Reported
Wrong drug administered
8 reports (7.3%)
All HUMALOG LISPRO, NPL Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Blood glucose increased | 26 | 23.9% | 0 | 13 |
| Hypoglycaemia | 9 | 8.3% | 1 | 6 |
| Dyspnoea | 8 | 7.3% | 1 | 5 |
| Incorrect dose administered | 8 | 7.3% | 0 | 3 |
| Malaise | 8 | 7.3% | 0 | 4 |
| Visual impairment | 8 | 7.3% | 0 | 3 |
| Wrong drug administered | 8 | 7.3% | 0 | 8 |
| Blood glucose decreased | 7 | 6.4% | 0 | 2 |
| Drug dose omission | 7 | 6.4% | 0 | 1 |
| Maternal exposure during pregnancy | 7 | 6.4% | 0 | 3 |
| Fall | 6 | 5.5% | 0 | 5 |
| Visual acuity reduced | 6 | 5.5% | 0 | 2 |
| Blindness | 5 | 4.6% | 0 | 0 |
| Glycosylated haemoglobin increased | 5 | 4.6% | 0 | 4 |
Who Reports HUMALOG LISPRO, NPL Side Effects? Age & Gender Data
Average age: 56.6 years. Most reports from: US. View detailed demographics →
Is HUMALOG LISPRO, NPL Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 2 | 0 | 1 |
| 2004 | 1 | 0 | 0 |
| 2007 | 1 | 0 | 0 |
| 2008 | 1 | 1 | 1 |
| 2010 | 3 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 5 | 0 | 4 |
| 2013 | 17 | 0 | 9 |
| 2014 | 20 | 0 | 12 |
What Is HUMALOG LISPRO, NPL Used For?
| Indication | Reports |
|---|---|
| Type 2 diabetes mellitus | 44 |
| Diabetes mellitus | 32 |
| Product used for unknown indication | 17 |
| Gestational diabetes | 7 |
| Type 1 diabetes mellitus | 7 |
HUMALOG LISPRO, NPL vs Alternatives: Which Is Safer?
HUMALOG LISPRO, NPL vs HUMAN C1-ESTERASE INHIBITOR
HUMALOG LISPRO, NPL vs HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX
HUMALOG LISPRO, NPL vs HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN
HUMALOG LISPRO, NPL vs HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN
HUMALOG LISPRO, NPL vs HUMAN IMMUNOGLOBULIN G
HUMALOG LISPRO, NPL vs HUMAN IMMUNOGLOBULIN G\HYALURONIDASE
HUMALOG LISPRO, NPL vs HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN
HUMALOG LISPRO, NPL vs HUMAN PAPILLOMAVIRUS QUADRIVALENT VACCINE, RECOMBINANT
HUMALOG LISPRO, NPL vs HUMAN RABIES VIRUS IMMUNE GLOBULIN
HUMALOG LISPRO, NPL vs HUMAN RHO IMMUNE GLOBULIN
Official FDA Label for HUMALOG LISPRO, NPL
Official prescribing information from the FDA-approved drug label.